07 Apr 2021 Comment LoA Update: Amryt’s Juxtapid sees 7-point surge in US approval prospects in familial chylomicronaemia due to positive investigator-led Phase III trial 07 Apr 2021
07 Apr 2021 Comment J&J’s double-dose Covid-19 vaccine draws differing expert reviews on US rollout with single-dose version already authorised 07 Apr 2021
05 Apr 2021 Comment Theravance’s Phase III ampreloxetine study needs dramatic improvement in neurogenic orthostatic hypotension to spur market uptake but trial success likely 05 Apr 2021
30 Mar 2021 Comment LoA Update: Novartis’ Lu-PSMA FDA approval shot in castration-resistant prostate cancer increases 8 points after Phase III efficacy signal 30 Mar 2021
26 Mar 2021 Comment Amryt’s Oleogel-S10 approvable in epidermolysis bullosa but initial burst of market momentum likely to stall with real-world experience 26 Mar 2021
19 Mar 2021 Comment BMC Paediatrics to have imminent publication of peer-reviewed manuscript on first known case of an infant with maternal antibodies prompted by a Covid-19 vaccine, coauthor says 19 Mar 2021
18 Mar 2021 Comment Eli Lilly’s Phase II merestinib plunges 2 points after data shows no PFS improvement in 1L biliary tract cancer 18 Mar 2021
15 Mar 2021 Comment LoA Update: Scynexis’ ibrexafungerp sees 3-point increase in US approval potential with positive interim Phase III systemic candidiasis data 15 Mar 2021
15 Mar 2021 Comment LoA Update: Regeneron’s chance at an FDA nod for its cat allergy treatment for mild asthma patients jumps 8 points on Phase II data 15 Mar 2021
15 Mar 2021 Comment LoA Update: Locus’ UTI therapy sees 2-point decrease in FDA approval shot despite positive Phase Ib, but still has 92% possibility of regulatory success 15 Mar 2021
